Pinnacle Bank lifted its position in shares of Zoetis Inc (NYSE:ZTS) by 9.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,658 shares of the company’s stock after purchasing an additional 220 shares during the quarter. Pinnacle Bank’s holdings in Zoetis were worth $364,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mercer Capital Advisers Inc. raised its holdings in shares of Zoetis by 2.9% in the 1st quarter. Mercer Capital Advisers Inc. now owns 3,575 shares of the company’s stock valued at $421,000 after acquiring an additional 100 shares in the last quarter. Weiss Multi Strategy Advisers LLC purchased a new stake in shares of Zoetis during the 1st quarter valued at about $445,000. Forsta AP Fonden lifted its stake in shares of Zoetis by 244.2% in the 1st quarter. Forsta AP Fonden now owns 91,900 shares of the company’s stock worth $10,816,000 after purchasing an additional 65,200 shares during the period. Alps Advisors Inc. grew its position in Zoetis by 62.4% during the first quarter. Alps Advisors Inc. now owns 20,051 shares of the company’s stock valued at $2,360,000 after buying an additional 7,704 shares during the period. Finally, Franklin Resources Inc. increased its holdings in Zoetis by 229.2% during the fourth quarter. Franklin Resources Inc. now owns 220,685 shares of the company’s stock valued at $29,208,000 after buying an additional 153,654 shares during the last quarter. Institutional investors and hedge funds own 91.45% of the company’s stock.
In other news, EVP Heidi C. Chen sold 1,179 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $127.44, for a total value of $150,251.76. Following the sale, the executive vice president now owns 17,514 shares of the company’s stock, valued at $2,231,984.16. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Kristin C. Peck sold 10,500 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $131.31, for a total transaction of $1,378,755.00. Following the completion of the sale, the chief executive officer now owns 43,759 shares of the company’s stock, valued at approximately $5,745,994.29. The disclosure for this sale can be found here. Insiders have sold 18,500 shares of company stock worth $2,439,082 over the last three months. 0.17% of the stock is currently owned by insiders.
Shares of NYSE ZTS traded up $0.73 during midday trading on Tuesday, reaching $139.33. 544,562 shares of the stock traded hands, compared to its average volume of 1,626,845. The company’s 50 day moving average is $135.77 and its 200 day moving average is $131.49. Zoetis Inc has a one year low of $90.14 and a one year high of $146.26. The company has a debt-to-equity ratio of 2.22, a current ratio of 2.77 and a quick ratio of 1.91. The stock has a market capitalization of $65.38 billion, a PE ratio of 41.37, a P/E/G ratio of 4.90 and a beta of 0.77.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.95 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.86 by $0.09. Zoetis had a net margin of 25.41% and a return on equity of 67.72%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter last year, the business earned $0.88 earnings per share. Zoetis’s quarterly revenue was up 5.4% compared to the same quarter last year. As a group, equities analysts forecast that Zoetis Inc will post 3.33 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 17th will be given a $0.20 dividend. The ex-dividend date of this dividend is Thursday, July 16th. This represents a $0.80 annualized dividend and a yield of 0.57%. Zoetis’s dividend payout ratio is currently 21.98%.
A number of brokerages recently commented on ZTS. Argus reaffirmed a “buy” rating on shares of Zoetis in a report on Wednesday, June 3rd. Citigroup lowered their price objective on Zoetis from $139.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. UBS Group cut their price objective on Zoetis from $146.00 to $126.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. G.Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Tuesday, March 31st. Finally, Morgan Stanley dropped their price target on shares of Zoetis from $148.00 to $125.00 and set an “equal weight” rating for the company in a research report on Thursday, April 2nd. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $142.36.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: Understanding Specialty Certificates of Deposit
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.